Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.

[1]  B. Becher,et al.  IL-12 initiates tumor rejection via lymphoid tissue–inducer cells bearing the natural cytotoxicity receptor NKp46 , 2010, Nature Immunology.

[2]  G. Trinchieri,et al.  Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. , 2010, Cancer research.

[3]  S. Rosenberg,et al.  CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma , 2010, Clinical Cancer Research.

[4]  S. Rosenberg,et al.  Enrichment of CD8+ Cells From Melanoma Tumor-infiltrating Lymphocyte Cultures Reveals Tumor Reactivity for Use in Adoptive Cell Therapy , 2010, Journal of immunotherapy.

[5]  Q. Ding,et al.  Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. , 2010, Cancer letters.

[6]  B. Shalmon,et al.  Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients , 2010, Clinical Cancer Research.

[7]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[8]  S. Rosenberg,et al.  Adoptive cell therapy for the treatment of patients with metastatic melanoma. , 2009, Current opinion in immunology.

[9]  J. Wargo,et al.  Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression , 2009, Cancer Immunology, Immunotherapy.

[10]  Richard Heller,et al.  Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Rosenberg,et al.  Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Yuquan Wei,et al.  A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  J. Weiss,et al.  Immunotherapy of cancer by IL-12-based cytokine combinations , 2007, Expert opinion on biological therapy.

[14]  M. Del Vecchio,et al.  Interleukin-12: Biological Properties and Clinical Application , 2007, Clinical Cancer Research.

[15]  D. Mahvi,et al.  Intratumoral injection of IL-12 plasmid DNA – results of a phase I/IB clinical trial , 2007, Cancer Gene Therapy.

[16]  A. Schambach,et al.  Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  K. Moelling,et al.  Anti‐tumor activity of mesenchymal stem cells producing IL‐12 in a mouse melanoma model , 2006, Experimental dermatology.

[18]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[19]  S. Rosenberg,et al.  Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR , 2005, The Journal of Immunology.

[20]  S. Rosenberg,et al.  Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. , 2005, Human gene therapy.

[21]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Holland,et al.  Defects in the interferon‐γ and interleukin‐12 pathways , 2005, Immunological reviews.

[23]  S. Rosenberg,et al.  Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer , 2004, Journal of leukocyte biology.

[24]  H. Heslop,et al.  A strategy for treatment of Epstein–Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells , 2004, Cancer Gene Therapy.

[25]  S. Rosenberg,et al.  High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens , 2003, The Journal of Immunology.

[26]  S. Rosenberg,et al.  Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells , 2003, The Journal of experimental medicine.

[27]  Y. Sung,et al.  Inhibition of TCR-Induced CD8 T Cell Death by IL-12: Regulation of Fas Ligand and Cellular FLIP Expression and Caspase Activation by IL-121 , 2003, The Journal of Immunology.

[28]  G. Dunston,et al.  IL-12 plays a significant role in the apoptosis of human T cells in the absence of antigenic stimulation. , 2002, Cytokine.

[29]  C. H. Park,et al.  Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. , 2001, Human gene therapy.

[30]  M. Atkins,et al.  Clinical use of systemic IL-12 therapy. , 2001, Cancer chemotherapy and biological response modifiers.

[31]  A. Bakker,et al.  NFAT-controlled expression of GFP permits visualization and isolation of antigen-stimulated primary human T cells. , 2000, Blood.

[32]  P. Musiani,et al.  Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. , 1999, Cancer research.

[33]  B. Car,et al.  The Toxicology of Interleukin-12: A Review , 1999, Toxicologic pathology.

[34]  J. Leonard,et al.  Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production , 1997 .

[35]  G. Trinchieri,et al.  The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12. , 1997, Cancer research.

[36]  M. Atkins,et al.  Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  R. Mulligan,et al.  Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo , 1997, Nature Biotechnology.

[38]  L. Zitvogel,et al.  Murine Models of Cancer Cytokine Gene Therapy Using Interleukin‐12 a , 1996, Annals of the New York Academy of Sciences.

[39]  M. Colombo,et al.  Amount of interleukin 12 available at the tumor site is critical for tumor regression. , 1996, Cancer research.

[40]  T. Idziorek,et al.  T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)- mediated apoptosis of CD4+ T cells from human immunodeficiency virus- infected persons , 1995, The Journal of experimental medicine.

[41]  J Cohen,et al.  IL-12 Deaths: Explanation and a Puzzle , 1995, Science.

[42]  K. Takase,et al.  [T cell activation]. , 1995, Ryumachi. [Rheumatism].

[43]  K. Grabstein,et al.  Interleukin‐12 regulates the proliferation of Th1, but not Th2 or Th0, clones , 1994, European journal of immunology.

[44]  L. Luistro,et al.  Antitumor and antimetastatic activity of interleukin 12 against murine tumors , 1993, The Journal of experimental medicine.

[45]  J. Siegel,et al.  Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. , 1993, Journal of immunology.

[46]  G. Trinchieri,et al.  Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells , 1993, The Journal of experimental medicine.

[47]  M. Gately,et al.  Interleukin-12: a recently discovered cytokine with potential for enhancing cell-mediated immune responses to tumors. , 1993, Cancer investigation.

[48]  N. Shastri,et al.  Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[49]  P. Familletti,et al.  Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[50]  G. Trinchieri,et al.  Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes , 1989, Journal of Experimental Medicine.